| Molecular formula | C207H317N45O65 |
| Molecular weight | 4476 g/mol |
| Registered trials | 46 |
| PubChem CID | 167312357 |
What mazdutide is
Mazdutide, also known as IBI362, is an investigational peptide that has not received approval from any regulatory agency and carries no approved drug label. It is being studied as part of an active research program rather than offered as an approved medicine. Its chemical identity is catalogued under PubChem CID 167312357.
Trial footprint
Mazdutide has 46 registered clinical trials. Among the publicly listed studies, one phase 3 trial is comparing mazdutide to semaglutide in Chinese overweight or obese adults with metabolic dysfunction-associated fatty liver disease and is active but not recruiting. Other listed studies include a trial examining mazdutide as adjuvant therapy following sleeve gastrectomy in severe obesity, which has not yet begun recruiting, and a separate study of GLP-1 therapy after bariatric surgery in Chinese patients with obesity that is currently recruiting. These entries describe the scope of ongoing research rather than any demonstrated outcome.
FAQ
No. Mazdutide has no approved drug label and remains an investigational compound. It is being evaluated only within registered clinical trials.
Registered trials involving mazdutide include research in obesity, metabolic dysfunction-associated fatty liver disease, and use following bariatric surgery. These are ongoing studies, not confirmed uses.
There are 46 registered clinical trials listed for mazdutide. These span different stages, from not yet recruiting to active, not recruiting.
Yes. IBI362 is another name used for mazdutide in trial registries and research literature.
No side effect report data is currently available for mazdutide in this summary. Safety information for investigational compounds is typically limited to data collected within clinical trials.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-11-07